SEC Form 4 · accession 0000105770-26-000108

WEST PHARMACEUTICAL SERVICES INC · WST

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Sr. VP & Chief HR Officer

Period of report

Sep 8, 2026

Accepted (ET)

Sep 10, 2026 · 5:36 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0000105770

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Sep 8, 2026	M	2,817	$83.47	A	19,662	D
Common Stock^F1	Sep 8, 2026	S	2,817	$340.81	D	16,845	D
Common Stock	Sep 8, 2026	M	2,818	$83.47	A	19,663	D
Common Stock^F1	Sep 8, 2026	S	2,818	$340.81	D	16,845	D
Common Stock	Sep 8, 2026	M	2,500	$89.64	A	19,345	D
Common Stock^F1	Sep 8, 2026	S	2,500	$340.81	D	16,845	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Options (Right to Buy)^F2	$83.47	Sep 8, 2026	M	2,817	D	—	Feb 21, 2027	Common Stock	2,817	2,818	D
Stock Options (Right to Buy)^F2	$83.47	Sep 8, 2026	M	2,818	D	—	Feb 21, 2027	Common Stock	2,818	0	D
Stock Option (Right to Buy)^F3	$89.64	Sep 8, 2026	M	2,500	D	—	Feb 20, 2028	Common Stock	2,500	7,524	D

F1The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price resulting in such weighted average price.
F2This award granted on February 21, 2017 vested in four equal annual installments beginning on February 21, 2018.
F3This award granted on February 20, 2018 vested in four equal annual installments beginning on February 20, 2019.